Summit Therapeutics (NASDAQ:SMMT) Announces Earnings Results

Summit Therapeutics (NASDAQ:SMMT) issued its earnings results on Thursday. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01), Zacks reports.

Here are the key takeaways from Summit Therapeutics’ conference call:

• Updated HARMONi OS data showed a hazard ratio of 0.76 in both the total population and Western patients, with management saying the benefit remained consistent as follow-up matured. The company also said no new safety signals emerged.
• HARMONi-3 has completed enrollment in both squamous and non-squamous cohorts, and management still expects a PFS readout for the squamous cohort in the second half of this year. They also highlighted an interim OS look in the first half of 2027.
• Ivonescimab pipeline expansion continues across multiple tumor types, including colorectal cancer and head and neck cancer, with the company emphasizing over 65 investigator-sponsored trials and multiple active global phase III studies. Management framed this as evidence of broad physician interest and platform potential.
• FDA review of the BLA for ivonescimab plus chemo in EGFR-mutated NSCLC remains ongoing, with a PDUFA date of November 14 and the updated OS analysis already submitted to the agency. Management said it does not expect the date to move, but deferred to the FDA on any further action.
• Financial position remained strong at about $690.7 million in cash, aided by ATM financing, while second-quarter operating expenses rose due to heavier R&D spending on HARMONi-GI3, HARMONi-3, and HARMONi-7. The company also filed for a new $380 million ATM to preserve flexibility.

Summit Therapeutics Price Performance

Shares of SMMT stock traded down $1.00 on Friday, hitting $13.98. The stock had a trading volume of 3,167,190 shares, compared to its average volume of 3,949,230. The firm has a market capitalization of $10.85 billion, a P/E ratio of -8.69 and a beta of -1.26. Summit Therapeutics has a 1 year low of $12.55 and a 1 year high of $30.98. The company’s 50 day moving average price is $15.09 and its 200-day moving average price is $16.70.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Summit Therapeutics in a research note on Friday. HC Wainwright reaffirmed a “neutral” rating on shares of Summit Therapeutics in a research report on Thursday. Stifel Nicolaus decreased their price objective on Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Friday. KeyCorp reiterated an “overweight” rating on shares of Summit Therapeutics in a research report on Monday, June 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Summit Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Summit Therapeutics has a consensus rating of “Hold” and a consensus target price of $26.15.

Insider Activity at Summit Therapeutics

In other news, CFO Manmeet Singh Soni bought 50,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was bought at an average cost of $14.45 per share, with a total value of $722,500.00. Following the transaction, the chief financial officer directly owned 3,123,603 shares in the company, valued at $45,136,063.35. The trade was a 1.63% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mahkam Zanganeh purchased 3,810,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were acquired at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the completion of the purchase, the chief executive officer directly owned 573,883,879 shares of the company’s stock, valued at approximately $7,529,356,492.48. This trade represents a 0.67% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 7,870,000 shares of company stock worth $103,616,900 in the last three months. 83.50% of the stock is owned by company insiders.

Institutional Trading of Summit Therapeutics

A number of large investors have recently modified their holdings of SMMT. Hudson Bay Capital Management LP purchased a new stake in shares of Summit Therapeutics in the 4th quarter valued at approximately $200,000. State of Wyoming purchased a new stake in shares of Summit Therapeutics during the 4th quarter worth $202,000. Oxford Asset Management LLP purchased a new stake in shares of Summit Therapeutics during the 2nd quarter worth $245,000. California State Teachers Retirement System grew its stake in shares of Summit Therapeutics by 62.3% during the second quarter. California State Teachers Retirement System now owns 7,368 shares of the company’s stock worth $157,000 after purchasing an additional 2,828 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Summit Therapeutics during the second quarter worth $249,000. Hedge funds and other institutional investors own 4.61% of the company’s stock.

Key Stories Impacting Summit Therapeutics

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: Investor interest in Summit Therapeutics surged in options markets, with call volume jumping sharply above normal levels, suggesting some traders are positioning for a rebound or upcoming catalyst. MarketBeat SMMT options news
• Positive Sentiment: Summit and Arcus Biosciences announced a clinical trial collaboration to evaluate casdatifan combined with ivonescimab in kidney cancer, expanding ivonescimab’s development program and potential market opportunities. Arcus Biosciences and Summit Therapeutics collaboration
• Positive Sentiment: The company said ivonescimab continues to show clinical momentum, with updated survival data from the HARMONi study and broader late-stage development progress supporting the long-term investment case. Zacks updated ivonescimab survival data
• Positive Sentiment: Analysts noted improving survival data and the FDA acceptance of the BLA for ivonescimab plus chemotherapy in EGFR-mutant NSCLC, which keeps a major regulatory catalyst in focus. Seeking Alpha rating upgrade article
• Neutral Sentiment: Summit’s earnings call transcript and presentation highlighted operational progress, but these items largely repeat the company’s existing clinical update rather than adding a new major catalyst. Q2 2026 earnings call transcript
• Negative Sentiment: Q2 results showed a wider loss than expected and no revenue, which is weighing on sentiment and reinforcing the company’s ongoing dependence on clinical execution rather than commercial sales. Business Wire Q2 results

About Summit Therapeutics

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.